This company is no longer active
MorphoSys Balance Sheet Health
Financial Health criteria checks 2/6
MorphoSys has a total shareholder equity of €-261.7M and total debt of €1.7B, which brings its debt-to-equity ratio to -658%. Its total assets and total liabilities are €1.8B and €2.1B respectively.
Key information
-658.00%
Debt to equity ratio
€1.72b
Debt
| Interest coverage ratio | n/a |
| Cash | €630.77m |
| Equity | -€261.67m |
| Total liabilities | €2.09b |
| Total assets | €1.83b |
Recent financial health updates
Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Recent updates
Financial Position Analysis
Short Term Liabilities: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MOR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MOR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MOR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MOR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 35.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/05 06:55 |
| End of Day Share Price | 2024/08/05 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MorphoSys AG is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olav Zilian | Baader Helvea Equity Research |
| Brian Balchin | Barclays |
| Rosie Turner | Barclays |